Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
TGF-beta signaling pathway impairment causes refractoriness to doxorubicin
September 15th, 2005
Tranforming growth factor beta (TGF-beta) pathway impairment causes refractoriness of used tumor cells to the anti-cancer drug doxorubicin. In a recent study published in the journal Experimental Oncology, I. Chorna and associates at the Institute of Cell Biology in Lviv, Ukraine reported, "The effect of X-irradiation on the expression of mRNAs coding for transforming growth factor beta (TGF-beta) and its receptors was compared in human breast carcinoma MCF-7 cells differing in their sensitivity to doxorubicin." The researchers reported, "Semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was used for the estimation of...
Source: Women's Health Weekly (2005-09-15)
|
